Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 13, 2013 - Issue 3
Submit an article Journal homepage
355
Views
16
CrossRef citations to date
0
Altmetric
Research Report

Cost–utility analysis of nanoparticle albumin-bound paclitaxel versus paclitaxel in monotherapy in pretreated metastatic breast cancer in Spain

Emilio Alba Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain
,
Eva Ciruelos Hospital 12 de Octubre, Madrid, Spain
,
Rafael López Complejo Hospitalario Universitario de Santiago de Compostela, Santiago, Spain
,
José Manuel López-Vega Hospital Universitario Marqués de Valdecilla, Santander, Spain
,
Ana Lluch Hospital Clínic Universitari, Valencia, Spain
,
Miguel Martín Instituto de Investigación Sanitaria Hospital Gregorio Marañón, Madrid, Spain
,
Montserrat Muñoz Hospital Clínic i Provincial, Barcelona, Spain
,
Pedro Sánchez-Rovira Complejo Hospitalario de Jaén, Jaén, Spain; Complejo Hospitalario de Jaén, Jaén, Spain
,
Miguel Ángel Seguí Corporació Sanitaria Parc Taulí, Sabadell, Spain; Corporació Sanitaria Parc Taulí, Sabadell, Spain
,
COSTABRAX Working Group Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain
,
Marta Rubio Liria Celgene SL, Madrid, Spain; Celgene SL, Madrid, Spain
&
Ferran Pérez-Alcántara Oblikue Consulting SL, Barcelona, Spain. [email protected]
 show all
Pages 381-391 | Published online: 09 Jan 2014

References

  • Sánchez-Muñoz A, Perez-Ruiz E, Ribelles N, Márquez A, Alba E. Maintenance treatment in metastatic breast cancer. Expert Rev. Anticancer Ther. 8(12), 1907–1912 (2008).
  • Smigal C, Jemal A, Ward E et al. Trends in breast cancer by race and ethnicity: update 2006. CA Cancer J. Clin. 56(3), 168–183 (2006).
  • Verma S, Clemons M. First-line treatment options for patients with HER-2 negative metastatic breast cancer: the impact of modern adjuvant chemotherapy. Oncologist 12(7), 785–797 (2007).
  • Early Breast Cancer Trialists’ Collaborative Group (EBCTCG); Peto R, Davies C, Godwin J et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379, 432–444 (2012).
  • Gradishar WJ. Albumin-bound paclitaxel: a next-generation taxane. Expert Opin. Pharmacother. 7(8), 1041–1053 (2006).
  • Stinchcombe TE. Nanoparticle albumin-bound paclitaxel: a novel Cremphor-EL-free formulation of paclitaxel. Nanomedicine (Lond.) 2(4), 415–423 (2007).
  • Gradishar WJ, Tjulandin S, Davidson N et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J. Clin. Oncol. 23(31), 7794–7803 (2005).
  • López Bastida J, Oliva J, Antoñanzas F et al. A proposed guideline for economic evaluation of health technologies. Gac. Sanit. 24(2), 154–170 (2010).
  • Mar J, Antoñanzas F, Pradas R, Arrospide A. Probabilistic Markov models in economic evaluation of health technologies: a practical guide. Gac. Sanit. 24(2), 209–214 (2010).
  • Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J. Clin. Epidemiol. 50(6), 683–691 1997.
  • Song F, Altman DG, Glenny AM, Deeks JJ. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. Br. Med. J. 326(7387), 472–475 (2003).
  • Seidman AD, Berry D, Cirrincione C et al. Randomized Phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of cancer and leukemia group B protocol 9840. J. Clin. Oncol. 26(10), 1642–1649 (2008).
  • Cooper NJ, Abrams KR, Sutton AJ, Turner D, Lambert PC. A Bayesian approach to Markov modelling in cost–effectiveness analyses: application to taxane use in advanced breast cancer. J. R. Stat. Soc. Ser. A Stat. Soc. 166(3), 389–405 (2003).
  • Frías C, Cortés J, seguí MA, Oyagüez I, Casado MA. Cost–effectiveness analyses of docetaxel versus paclitaxel once weekly in patients with metastatic breast cancer in progression following anthracycline chemotherapy in Spain. Clin. Transl. Oncol. 12(10), 692–700 (2010).
  • Claxton K, Schupher M, McCabe C et al. Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health Econ. 14(4), 339–347 (2005).
  • Sacristán JA, Oliva J, Del Llano J et al. What is an efficient health technology in Spain? Gac. Sanit. 16(4), 334–43 (2002).
  • Rodríguez-Barrios JM, Pérez-Alcántara F, Crespo Palomo C et al. The use of cost per life year gained as a measurement of cost–effectiveness in Spain: a systematic review of recent publications. Eur. J. Health Econ. 13(6), 723–740 (2012).
  • Rodriguez JM, Paz S, Lizan L, Gonzalez P. The use of quality-adjusted life years in the economic evaluation of health technologies in Spain: a review of the 1990–2009 literature. Value Health 14(4), 458–464 (2011).
  • McLeod E, Lloyd A, Samyshkin Y, Prunieras F, Canney P. A UK cost–utility analysis of paclitaxel albumin compared with solvent-based paclitaxel monotherapy and docetaxel monotherapy for pretreated metastatic breast cancer. Value Health 13(7), A269 (2010).
  • Dranitsaris G, Cottrell W, Spirovski B, Hopkins S. Economic analysis of albumin-bound paclitaxel for the treatment of metastatic breast cancer. J. Oncol. Pharm. Pract. 15(2), 67–78 (2009).
  • Dranitsaris G, Perayre Badia M, Clopes A, Fernández Ortega A, Rey Salido M. Cost utility analysis of nab-paclitaxel weekly or q3w compared with docetaxel q3w as first-line therapy in metastatic breast cancer (MBC). J. Clin. Oncol. 28, e1545 (2010).
  • Gradishar WJ, Krasnojon D, Cheporov S et al. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J. Clin. Oncol. 27(22), 3611–3619 (2009).
  • Dranitsaris G, Coleman R, Gradishar W. Nab-Paclitaxel weekly or every 3 weeks compared with standard docetaxel as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial. Breast Cancer Res. Treat. 119(3), 717–724 (2010).
  • Delea TE, Tappenden P, Sofrygin O et al. Cost–effectiveness of lapatinib plus capecitabine in women with HER2+ metastatic breast cancer who have received prior therapy with trastuzumab. Eur. J. Health Econ. 13(5), 589–603 (2012).
  • Dedes KJ, Matter-Walstra K, Schwenkglenks M et al. Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: an economic evaluation. Eur. J. Cancer 45(8), 1397–1406 (2009).
  • Song F, Harvey I, Lilford R. Adjusted indirect comparison may be less biased than direct comparison for evaluating new pharmaceutical interventions. Clin. Epidemiol. 61(5), 455–463 (2008).
  • Ojeda B, de Sande LM, Casado A, Merino P, Casado MA. Cost-minimisation analysis of pegylated liposomal doxorubicin hydrochloride versus topotecan in the treatment of patients with recurrent epithelial ovarian cancer in Spain. Br. J. Cancer 89(6), 1002–1007 (2003).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.